Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,622 JPY
Change Today +24.00 / 0.92%
Volume 2.4M
4568 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:00 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Open
¥2,632
Previous Close
¥2,598
Day High
¥2,642
Day Low
¥2,599
52 Week High
07/24/15 - ¥2,699
52 Week Low
01/16/15 - ¥1,556
Market Cap
1.9T
Average Volume 10 Days
2.2M
EPS TTM
¥66.43
Shares Outstanding
709.0M
EX-Date
09/28/15
P/E TM
39.5x
Dividend
¥60.00
Dividend Yield
2.29%
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

16,428 Employees
Last Reported Date: 05/14/15
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥131.0M
Compensation as of Fiscal Year 2014.

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo Company, Limited Announces European Commission Grants Marketing Authorisation for LIXIANA

Daiichi Sankyo Company, Limited announced that the European Commission (EC) has granted Marketing Authorisation for LIXIANA (edoxaban), an oral, once-daily selective factor Xa-inhibitor, for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age = 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA) as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Atrial fibrillation (AF), a heart rhythm disorder in which the heartbeat is rapid and irregular, affects over six million Europeans.[1] People with AF are at a five-fold increased risk of stroke compared to the general population, with an estimated financial burden of over €38 billion a year. VTE, a condition where a blood clot forms in a vein, also represents a major cause of morbidity and mortality, resulting in over 500,000 deaths in the EU each year. The EC approval is based on two phase 3 clinical trials, ENGAGE AF-TIMI 48 and Hokusai-VTE, which compared treatment with once-daily LIXIANA to warfarin, a current standard of care for stroke prevention in patients with AF or for the treatment and prevention of VTE. These studies represent the largest single comparative trials of a novel oral anticoagulant in these patient populations, involving 21,105 and 8,292 patients, respectively. In the ENGAGE AF-TIMI 48 study, once-daily LIXIANA showed comparable efficacy (stroke or SEs) in comparison to warfarin (1.18% vs. 1.50% per year, LIXIANA 60 mg vs. warfarin respectively; hazard ratio [HR], 0.79; 97.5% confidence interval [CI], 0.63 to 0.99, pAbout LIXIANA (edoxaban). ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) was a three-arm, randomized, double-blind, double-dummy, global phase 3 clinical trial comparing once-daily edoxaban with warfarin in 21,105 patients with NVAF at moderate-to-high risk of thromboembolic events at 1,393 centers in 46 countries. ENGAGE AF-TIMI 48 compared two edoxaban treatment strategies, a higher dose arm (60 mg or 30 mg dose reduced) once-daily and a lower dose arm (30 mg or 15 mg dose reduced) once-daily, with warfarin in patients with NVAF for a median of 2.8 years. Patients were dose reduced for creatinine clearance (CrCL) 30 to 50 mL/min, body weight of 60 kg or less or certain p-glycoprotein inhibitor use. ENGAGE AF-TIMI 48 represents the large and longest single comparative global trial with a novel anticoagulant in patients with NVAF performed to date. The full results were presented at the AHA Scientific Sessions 2013 in Dallas and published in the New England Journal of Medicine. Hokusai-VTE was a global, event-driven, randomized, double-blind, double-dummy, parallel-group phase 3 clinical study involving 8,292 patients in 439 clinical sites across 37 countries to evaluate once-daily edoxaban with warfarin in patients with either acute symptomatic DVT, PE or both. The Hokusai-VTE study was designed to reflect clinical practice using a flexible treatment duration of 3-12 months in a broad spectrum of VTE patients, including initial use of parenteral anticoagulant (heparin) for at least 5 days, the proven global standard of care.

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

Daiichi Sankyo Company, Limited announced the initiation of Hokusai-VTE Cancer, a multinational study which will investigate the efficacy and safety of edoxaban, an oral, once-daily selective factor Xa inhibitor, versus dalteparin for the treatment of VTE associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term treatment with a low molecular weight heparin (LMWH) is intended.[1] The purpose of the study is to evaluate edoxaban in comparison with dalteparin in preventing the combined outcome of VTE recurrence or major bleeding following an acute deep vein thrombosis (DVT) or pulmonary embolism (PE) event in patients with cancer. The recruitment has started, and approximately 1,000 patients are expected to be enrolled in the study at clinical sites across 13 countries. Edoxaban is currently marketed in Japan, the U.S., and Switzerland, and has also been recommended for approval in the EU by the European Committee for Medicinal Products for Human Use (CHMP). In other countries, regulatory review is ongoing.

Daiichi Sankyo Company, Limited Presents at BIO International Convention 2015, Jun-16-2015 02:00 PM

Daiichi Sankyo Company, Limited Presents at BIO International Convention 2015, Jun-16-2015 02:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Mark Dennish, Vice President, Business Development, New Product Planning and Oncology Franchise.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥2,621.50 JPY +24.00

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $15.72 USD +0.66
BioMerieux €105.85 EUR +0.40
Exelixis Inc $5.41 USD -0.03
Ipsen SA €57.15 EUR +0.48
Vertex Pharmaceuticals Inc $128.30 USD +5.07
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 38.2x
Price/Sales 1.9x
Price/Book 1.4x
Price/Cash Flow 5.6x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.